Scarica l'app Stockscreener
3.76
3.84%
-0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.91
Aprire:
$3.94
Volume 24 ore:
514.05K
Relative Volume:
0.59
Capitalizzazione di mercato:
$328.76M
Reddito:
$32.77M
Utile/perdita netta:
$-101.98M
Rapporto P/E:
-0.3913
EPS:
-9.6101
Flusso di cassa netto:
$-112.43M
1 W Prestazione:
-2.08%
1M Prestazione:
+2.73%
6M Prestazione:
+33.33%
1 anno Prestazione:
-81.30%
Intervallo 1D:
$3.76
$4.00
Intervallo di 1 settimana:
$3.525
$4.0784
Portata 52W:
$1.35
$26.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Nome
X 4 Pharmaceuticals Inc
Settore
Industria
Telefono
857-529-8300
Indirizzo
61 NORTH BEACON STREET, BOSTON, MA
Confronta XFOR con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.76 | 341.88M | 32.77M | -101.98M | -112.43M | -9.6101 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-05 | Ripresa | Stifel | Buy |
| 2023-12-12 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Ripresa | B. Riley Securities | Buy |
| 2022-12-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
| 2019-12-23 | Iniziato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | ROTH Capital | Buy |
| 2019-12-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-12-05 | Iniziato | B. Riley FBR | Buy |
| 2019-06-07 | Iniziato | Stifel | Buy |
| 2019-06-05 | Iniziato | Cowen | Outperform |
Mostra tutto
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
Weekly Analysts’ Ratings Changes for X4 Pharmaceuticals (XFOR) - Defense World
Aug Opening: Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Technical Overview & Verified Chart Pattern Trade Signals - moha.gov.vn
Bain Capital Life Sciences Investors LLC Sells 16,351,925 Shares of X4 Pharmaceuticals, Inc. $XFOR - MarketBeat
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Acorn Capital Advisors LLC - MarketBeat
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Acadia Pharmaceuticals Announces FDA Approval of DAYBUE® STIX (trofinetide) for Oral Solution, a New Powder Formulation of Trofinetide for the Treatment of Rett Syndrome - Markets Financial Content
Layoff Tracker: Pfizer, Geron Downsize To Streamline Costs - BioSpace
X4 PharmaSeizing Rare Opportunities, Not Acting On A Whim - RTTNews
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Does X4 Pharmaceuticals Inc (XFOR) offer a good opportunity for investors? - setenews.com
X4 Pharmaceuticals, Inc. $XFOR Shares Sold by Pale Fire Capital SE - MarketBeat
Tracking the Evolving Narrative for X4 Pharmaceuticals After Financing and Restructuring Moves - Yahoo Finance
Blood pressure drug recalled for possible cross-contamination - USA Today
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
XFOR Stock Update: Stifel Raises Target Price to $10.00 | XFOR S - GuruFocus
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness - BioSpace
Stronger 2025 Outlook And Fragile X Trial Start Might Change The Case For Investing In Mirum (MIRM) - Yahoo Finance
How X4 Pharmaceuticals Inc. stock reacts to oil prices2025 Technical Overview & Stepwise Swing Trade Plans - Newser
Is X4 Pharmaceuticals Inc. (48Q0) stock a safe buy pre earningsFed Meeting & Intraday High Probability Alerts - Newser
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times
Take off with X4 Pharmaceuticals Inc (XFOR): Get ready for trading - Setenews
Why pension funds invest in X4 Pharmaceuticals Inc. (48Q0) stockWeekly Earnings Recap & Weekly Breakout Opportunity Watchlist - Newser
Is X4 Pharmaceuticals Inc. stock positioned for long term growthJuly 2025 Gainers & Comprehensive Market Scan Reports - Newser
Will X4 Pharmaceuticals Inc. (48Q0) stock profit from AI boomTrade Ideas & Fast Exit and Entry Strategy Plans - Newser
An analyst sees good growth prospects for Nano X Imaging Ltd (NNOX) - Setenews
X4 Pharmaceuticals: Betting On Mavorixafor For Chronic Neutropenia (NASDAQ:XFOR) - Seeking Alpha
Mirum Pharmaceuticals Announces First Patient Enrolled in the BLOOM Phase 2 Clinical Study Evaluating MRM-3379 in Fragile X Syndrome - Yahoo Finance
X4 Pharmaceuticals (NASDAQ:XFOR) Stock Rating Lowered by Wall Street Zen - Defense World
SKYRIZI® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance - Investing News Network
Will X4 Pharmaceuticals Inc. stock deliver long term returns2025 Momentum Check & Free High Accuracy Swing Entry Alerts - moha.gov.vn
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness - Morningstar
Can X4 Pharmaceuticals Inc. stock deliver sustainable ROE2025 Macro Impact & Low Volatility Stock Recommendations - moha.gov.vn
Earnings Report: Can X4 Pharmaceuticals Inc. stock sustain institutional interestTrade Risk Summary & AI Powered Buy and Sell Recommendations - moha.gov.vn
Investors Don't See Light At End Of Universe Pharmaceuticals INC's (NASDAQ:UPC) Tunnel And Push Stock Down 31% - simplywall.st
Looking at the Narrative for X4 Pharmaceuticals After Leadership Changes and New Financing - Yahoo Finance
Head-To-Head Contrast: Werewolf Therapeutics (NASDAQ:HOWL) versus X4 Pharmaceuticals (NASDAQ:XFOR) - Defense World
X4 Pharmaceuticals (NASDAQ:XFOR) Upgraded to Hold at Wall Street Zen - Defense World
Is X4 Pharmaceuticals Inc. stock positioned for digital transformation2025 Price Action Summary & Comprehensive Market Scan Insights - newser.com
Why X4 Pharmaceuticals Inc. (48Q0) stock remains top ratedWeekly Trend Report & AI Enhanced Trading Alerts - newser.com
Will X4 Pharmaceuticals Inc. stock remain a Wall Street favorite2025 Short Interest & Growth Oriented Trading Recommendations - newser.com
X4 Pharmaceuticals Inc (XFOR) Performance and Fundamentals Dashboard tells a completely different story - Setenews
How to build a dashboard for X4 Pharmaceuticals Inc. stockWeekly Trade Analysis & Growth Oriented Trading Recommendations - newser.com
X 4 Pharmaceuticals Inc Azioni (XFOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):